Form 4: GE HealthCare Executive Philip Rackliffe Reports Stock and Option Awards
SEC Form 4 Filing
Philip Rackliffe, CEO of Ultrasound & IGT at GE HealthCare Technologies Inc., reports the acquisition of restricted stock units and an employee stock option.
Summary
- On August 15, 2024, Philip Rackliffe, CEO of Ultrasound & IGT at GE HealthCare Technologies Inc., reported transactions involving GE HealthCare securities.
- Rackliffe acquired 2,051 shares of common stock in the form of restricted stock units.
- These restricted stock units will vest in three tranches: 33% on September 1, 2025, 33% on September 1, 2026, and 34% on September 1, 2027, subject to certain conditions.
- Each restricted stock unit represents the right to receive one share of GE HealthCare common stock at settlement.
- Rackliffe also acquired an employee stock option for 6,203 shares of common stock with an exercise price of $85.30.
- This option also vests in three tranches: 33% on September 1, 2025, 33% on September 1, 2026, and 34% on September 1, 2027, subject to certain conditions.
- Following these transactions, Rackliffe directly owns 15,168 shares of GE HealthCare common stock and options for 6,203 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock and option awards, which is neither particularly positive nor negative.
Positives
- The award of restricted stock units and stock options to a key executive like Philip Rackliffe aligns his interests with the long-term performance of GE HealthCare.
- The vesting schedule encourages continued service and contribution to the company's success.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency into the equity holdings of key personnel.
Comparison to Industry Standards
- Stock option and restricted stock unit grants are a common component of executive compensation packages in the healthcare technology industry.
- Vesting schedules of three years are also typical to incentivize long-term commitment.
- Comparing the size of the grant to those of executives at similar companies like Siemens Healthineers or Philips could provide further context.
Stakeholder Impact
- The stock and option awards align the executive's interests with those of shareholders, potentially driving long-term value creation.
- Employees may view the awards as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 08/15/2024 | Date of transaction: Award of restricted stock units and employee stock option. |
| 08/19/2024 | Date of Form 4 filing. |
| 09/01/2025 | First vesting date for 33% of the restricted stock units and employee stock option. |
| 09/01/2026 | Second vesting date for 33% of the restricted stock units and employee stock option. |
| 09/01/2027 | Final vesting date for 34% of the restricted stock units and employee stock option. |
| 08/15/2034 | Expiration date of the employee stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.